

Erratum

'Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors' by

JS Meyer, M Province published in

BCRT 12(2): 191–204, 1988.

We regret that the last three lines of Table 1 and the titles of the lower panels of Fig. 4 of this paper contained errors as originally printed; the authors had provided corrections which were accidentally omitted. The two lower panels of Fig. 4 of course refer to Stage I, as correctly stated in the legend, not Stage II. The full correct version of Table 1 is printed below.

Table 1. Comparison of prognostic variables other than TLI at five years.

Class of patients and variable	No. patients	Absolute survival % ± SE*	P	Relapse-free survival % ± SE*	P
Histologic grade					
1	27	86 ± 8	0.06	72 ± 11	0.06
2	170	76 ± 4		66 ± 4	
3	510	67 ± 3		56 ± 3	
Nuclear grade					
1	133	86 ± 4	0.0002	80 ± 4	0.0004
2	215	72 ± 4		55 ± 4	
3	162	60 ± 5		54 ± 4	
Venous or lymphatic invasion at tumor-margin					
Present	139	58 ± 5	<0.0001	45 ± 5	<0.0001
Absent	379	77 ± 3		66 ± 3	
Estrogen receptor**					
0– 9 fm/mg	177	57 ± 5	0.001	54 ± 4	0.006
10–49 fm/mg	124	85 ± 4		67 ± 5	
50 + fm/mg	170	75 ± 4		62 ± 5	
Progesterone receptor**					
0– 9 fm/mg	210	78 ± 5	0.06 (NS)	61 ± 8	0.78 (NS)
10–49 fm/mg	66	78 ± 7		63 ± 8	
50 + fm/mg	140	68 ± 5		62 ± 6	

* Percent probability of survival ± standard error.

** In fmoles/mg cytosol protein.